Long-term Survival After Chemoradiotherapy Without Surgery for Rectal Adenocarcinoma: A Word of Caution
Early studies [1] [2] [3] [4] [5] with small samples from specialized centers report success with nonoperative management (NOM) or the watch-and-wait approach after neoadjuvant chemoradiotherapy for rectal adenocarcinoma. However, it is unknown whether the results are generalizable to the broader population of patients with rectal cancer. [1] [2] [3] [4] [5] Still, use of chemoradiotherapy without surgery has doubled among individuals with nonmetastatic rectal adenocarcinoma. 6 The highest use is observed among those who typically have lower access to innovative care: black patients, uninsured or Medicaid insured patients, and individuals treated at low-volume centers. 6 We suspected that this treatment approach in the community setting may often represent a disparity in appropriate care rather than an innovative and intentional treatment strategy. The outcomes for patients who receive chemoradiotherapy only outside a clinical trial are unknown. We hypothesized that this approach is associated with worse overall survival (OS).
Methods | The National Cancer Database, a hospital-based cancer registry, was used to identify incident cases of clinical stage II/III rectal adenocarcinoma from January 1, 2004, through December 31, 2008. The cohort was divided into 2 groups: chemoradiotherapy only and chemoradiotherapy plus proctectomy. To construct the cohort in such a way as to maximize the chance that patients in the chemoradiotherapy-only group would have been candidates for surgery, we restricted this group to only patients for whom it was reported that surgery was "not part of the planned first course of treatment." We calculated OS in months from date of diagnosis to last contact or confirmed death. We compared OS by treatment group using Kaplan-Meier survival curves and adjusted Cox proportional hazards models, controlling for patient, tumor, and facility characteristics. To account for immortal time bias, we excluded deaths that occurred in the year of diagnosis. The National Cancer Database analyses were each approved by and the need for informed consent waived by the University of North Carolina Institutional Review Board. All data were deidentified.
Results | Throughout the entire follow-up period, individuals receiving chemoradiotherapy only had poorer OS than those receiving chemoradiotherapy and proctectomy (hazard ratio, 1.90; 95% CI, 1.75-2.04) (Figure) . These differences persisted after adjusting for race, insurance status, and other factors independently associated with OS (adjusted hazard ratio, 1.69; 95% CI, 1.59-1.84) (Table) .
Discussion | Among a national sample of patients with clinical stage II/III rectal adenocarcinoma, patients treated with chemoradiotherapy only had inferior survival compared with conventional treatment. This finding is contrary to results of previously published single-institution and clinical trial reports on NOM. [1] [2] [3] [4] [5] This finding is likely because chemoradiotherapy only can be viewed at once as both an innovative treatment paradigm in some settings and low-quality care in others. Although NOM is an intentional approach for some patients, it is likely that many individuals forgoing surgery in the community are doing so as a result of systematic barriers. Our results point to disparities in the process of rectal cancer care where historically disadvantaged groups receive suboptimal care and experience worse outcomes. The finding that NOM is noninferior to conventional treatment for patients who have a complete response has received much attention. However, intensive follow-up is required for these patients. Although this type of surveillance is feasible with motivated patients in the context of a trial, substantial barriers may exist to ongoing follow-up in real-world settings.
Our study found inferior survival for patients treated with chemoradiotherapy only. From these data, we cannot know whether patients were receiving NOM and had a complete response to chemoradiotherapy or whether patients failed to receive surgery for other reasons. However, the results are concerning. As NOM becomes an increasingly accepted treatment approach, more comparative effectiveness studies evaluating outcomes in the real-world setting will be needed. Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer:
The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methods used or the conclusions drawn from these data by the investigator. 
COMMENT & RESPONSE

Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma
To the Editor In their interesting research letter, Bratman and colleagues 1 report that patients with head and neck squamous cell carcinoma associated with human papillomavirus (HPV) genotypes other than HPV-16 have inferior survival. They propose that this finding will affect patient selection in trials of treatment deintensification, which seek to minimize long-term toxic effects in patients with highly curable HPV-initiated oropharyngeal cancer. Data respecting the relative importance of p16 and HPV status in predicting outcome after chemoradiotherapy, as well as experience in cervical cancer, may be helpful in interpreting these results. In HPV-initiated cancers, HPV is found in the episomal form, integrated form, or in a combination of both. Viral integration results in a loss of negative feedback control of oncogene expression by the viral regulatory E2 protein. In addition to the oncogenic properties of E6 and E7, integration is suggested to be a driver of carcinogenesis. The E6 oncoprotein of high-risk HPVs binds and degrades the p53 tumor suppressor protein, while the HPV-E7 protein binds and degrades the retinoblastoma (Rb) tumor suppressor protein. Strong overexpression of the p16 protein is consistently found in HPV-associated cancers and correlates with HPV oncogenic potential. Weinberger et al 2 showed that p16 protein status determined by immunohistochemical analysis is a reliable surrogate marker for biologically and clinically meaningful HPV infection in oropharyngeal squamous cell carcinoma (OSCC), correlating with HPV viral load and inversely with Rb expression, and consistent with the cervical carcinogenesis model. In subsequent prospective studies in OSCC, 3-5 p16 protein status has repeatedly performed as the strongest predictive biomarker for improved progressionfree and overall survival in patients with OSCC treated with radiation or chemoradiation therapy. In the study by Bratman et al, 1 73 tumors expressed HPV transcripts, among which 61 were HPV-16 and 12 were HPV-other. The clinically validated biomarker p16 was available for only one-third of HPV-other genotype cases. Importantly, 41% of HPV-other genotypes were detected in the oral cavity or larynx, rather than in the oropharynx, the subsite for which HPV carcinogenesis is best understood. Do HPV-other genotypes display altered expression of viral genes compared with HPV-16, as suggested by the authors, or does the oncoviral gene expression profile not provide sufficient information for prognosis and treatment response prediction? Current trials of deintensification use p16 staining, T stage, and smoking history to identify favorable-risk patients.
Prospective study of HPV-other genotypes in OSCC, uniformly characterized with 16 staining and tobacco use history, and with uniform treatment, will be required before it becomes possible to conclude that HPV genotype alone can serve as a patient selection factor precluding deintensification.
